Press Releases

Date	Title	Company
20-Jan-2026	Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award	ACCESS Newswire
20-Jan-2026	Coulter Partners places Daniel Green as Chief Operating Officer at mOm Incubators	Coulter Partners
20-Jan-2026	Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT	Exciva
20-Jan-2026	Medivir presenting at the Redeye Fight Cancer Event 2026	Medivir
20-Jan-2026	Calitii, a Synechron company, secures Managed Services contract with BridgeBio to drive ServiceNow operational excellence	Calitii, a Synechron company
20-Jan-2026	Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis	Levicept Ltd
20-Jan-2026	Black Book Research Releases "New Zealand Acute Care EMR & Digital Health 2026" Companion Report	ACCESS Newswire
20-Jan-2026	Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA	ACCESS Newswire
20-Jan-2026	Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method	ACCESS Newswire
20-Jan-2026	Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection	Atopia Therapeutics
20-Jan-2026	Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office	ACCESS Newswire
20-Jan-2026	Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief	ACCESS Newswire
20-Jan-2026	Vygon appoints new general manager to lead German subsidiary	Andrew Lloyd Associates
20-Jan-2026	Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT	Andrew Lloyd Associates
20-Jan-2026	Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection	ACCESS Newswire
19-Jan-2026	SpineGuard Reports Its Full-year 2025 Revenue	Businesswire
19-Jan-2026	DeepHow Launches PharmaCloud to Standardize, Train, and Verify Operator Execution in Regulated Pharmaceutical Manufacturing	Businesswire
19-Jan-2026	DLA Piper Expands its Global Environmental Regulatory Practice with Adrián del Paso	Businesswire
19-Jan-2026	QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast	Businesswire
19-Jan-2026	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire